Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.43 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360959 | 0.95 | NISCH (0.47) | NISCHRUVBL1MAPTSMN1; SMN2KMT2A | |
| Formic Acid SCHEMBL4911292 | 0.83 | SMN1; SMN2 (0.36) | NISCHMAPTSMN1; SMN2KMT2A | |
| SCHEMBL4160968 | 0.80 | NISCH (0.51) | NISCHRUVBL1MAPTKMT2A | |
| Formic Acid SCHEMBL4911274 | 0.77 | NISCH (0.44) | NISCHRUVBL1MAPTKMT2A | |
| SCHEMBL4362117 | 0.77 | SMN1; SMN2 (0.40) | NISCHMAPTSMN1; SMN2KMT2A | |
| SCHEMBL4824118 | 0.73 | KCNH2 (0.47) | NISCHMAPTSMN1; SMN2KMT2A | |
| Formic Acid SCHEMBL4911286 | 0.68 | NISCH (0.37) | NISCH | |
| SCHEMBL4070597 | 0.67 | NISCH (0.51) | NISCHSMN1; SMN2KMT2A | |
| SCHEMBL4360835 | 0.67 | NISCH (0.53) | NISCHSMN1; SMN2KMT2A | |
| Formic Acid SCHEMBL4902744 | 0.66 | RUVBL1 (0.40) | NISCHRUVBL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | NISCH 1934/4885RUVBL1 339/4885HTT 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.